-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21

Benzinga·11/03/2026 17:22:14
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.